Clene (FRA:84C0) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:84C0 Clene Inc FRA:84C0
48 GF Score
Price €3.62
GF Value €1.01
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Clene Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:84C0
48GF Score
Clene Inc FRA:84C0
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Clene (FRA:84C0) Overvalued in 2026?

Based on GuruFocus' analysis, Clene stock appears to be overvalued. The current stock price of €3.62 is trading 258.4% above its estimated GF Value™ of €1.01. GuruFocus considers Clene to be Significantly Overvalued.

Key valuation signals for FRA:84C0:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €1.01 vs. price of €3.62 (258.4% above fair value)
  • GF Score™: 48/100 with 7 warning signs

No single metric tells the full story. See the FRA:84C0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clene Business Description

Other Exchanges CLNN:USA
Address 6550 South Millrock Drive, Suite G50, Salt Lake City, UT, USA, 84121
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
48GF Score

Get the complete analysis for FRA:84C0

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.62
Price
€1.01
GF Value